With stellar results in viral suppression and a 1 million patient population in the U.S. how will this not be lucrative? I've been in bio stocks where the ramp up to sales has been dreadfully slow, this is not one of those stocks. It already has quite a bit of buzz within the AIDS community.
Financing is the only thing that is potentially worrisome. But it really doesn't worry me. They cut a non-dilutive deal, no problem. They need to dilute, no problem. As long as the endpoint of FDA approval is accomplished the ends will more than justify the means.
I have enough confidence that Monday I will be more than doubling my position.
Market Data 
Markets 
AI
